Group 1 - The company, Beihai Kangcheng-B (01228), announced plans to issue a total of 9,996,200 subscription shares to three subscribers at a subscription price of HKD 2.26 per share, representing a discount of approximately 19.86% compared to the closing price of HKD 2.82 on September 15 [1] - The total amount raised from the subscription is estimated to be HKD 22,591,400, with a net amount of approximately HKD 22,091,400 after expenses [1] - The net proceeds from the subscription will be used for research and development expenses of existing product lines and for the company's daily operations [1]

Core Viewpoint - Beihai Kangcheng-B (01228) plans to issue a total of 9,996,200 subscription shares to three subscribers at a price of HKD 2.26 per share, representing a discount of approximately 19.86% compared to the closing price of HKD 2.82 on September 15 [1] Summary by Relevant Sections - **Subscription Details** - The company intends to issue shares to three subscribers: Qin Shen, Huang Xiaoting, and Wusong Capital Limited [1] - The total amount raised from the subscription is expected to be HKD 22,591,400, with a net amount of approximately HKD 22,091,400 after expenses [1] - **Use of Proceeds** - The net proceeds from the subscription will be allocated for research and development expenses related to existing product lines and for the company's daily operations [1]

Core Viewpoint - Kexuan Power Holdings (00476) has completed the subscription agreement as the conditions precedent have been met, resulting in the issuance of 60 million subscription shares at a price of HKD 0.45 per share, representing approximately 20.91% of the company's enlarged issued share capital [1] Group 1 - The subscription has generated net proceeds of approximately HKD 26.8 million, which will be utilized as disclosed in the circular [1]

Group 1 - The company, Sanofi Pharma-B, plans to issue 17.3524 million subscription shares to Huaxi Biotechnology (Hong Kong) Limited, Mr. Xie Shuohao, Bamboo Bloom Limited, and Capstone Resources Holding Limited [1] - This issuance represents approximately 14.16% of the company's enlarged issued share capital [1] - The subscription price is set at HKD 12.00 per share, which is a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [1] Group 2 - The total funds expected to be raised from this issuance are approximately HKD 208.2 million, with a net amount of about HKD 206 million [1] - The funds will be utilized for the company's general working capital [1]

Group 1 - The company plans to issue 17.3524 million subscription shares, representing approximately 14.16% of the enlarged issued share capital after the issuance [1] - The subscription price is set at HKD 12.00 per share, which is a discount of about 19.84% compared to the closing price of HKD 14.97 on September 5 [1] - The total amount raised from the subscription is expected to be approximately HKD 208.2 million, with a net amount of about HKD 206 million to be used for general working capital [1]

Core Viewpoint - WuXi AppTec (02268) announced a subscription agreement with WuXi Biologics (02269) to issue 24.134 million subscription shares at a price of HKD 58.85 per share, totaling approximately HKD 1.42 billion [1] Group 1 - The net proceeds from the subscription are approximately HKD 1.414 billion, with about 90% allocated for expanding the group's service capabilities and production capacity, including clinical and commercial production of bioconjugates, active pharmaceutical ingredients, and drugs [1] - Approximately 10% of the proceeds will be used for the group's working capital needs and general corporate purposes [1] - The subscriber is the controlling shareholder of the company, qualifying as a related party under the listing rules [1]

General Provisions - The company aims to protect the legal rights of the company, shareholders, employees, and creditors, and to regulate its organization and behavior according to relevant laws and regulations [1][4] - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2] - The registered capital of the company is 70 million RMB [3] Business Objectives and Scope - The company's business objective is to establish a new operating mechanism through joint investment by shareholders and to promote the Xgimi brand globally [4][5] - The business scope includes software development, technical services, manufacturing of household appliances, and various sales and advertising activities [5] Shares - The company's shares are in the form of stocks, including domestic shares (A-shares) and overseas listed shares (H-shares) [7] - The issuance of shares follows principles of openness, fairness, and justice, ensuring equal rights for each share of the same category [7][8] - The company has a total of 3,675,000 shares issued, with specific details on the shareholding structure provided [8] Shareholders and Shareholder Meetings - The company recognizes the rights of shareholders to receive dividends, participate in meetings, and supervise the company's operations [16][35] - Shareholders holding more than 10% of shares can request the board to convene a temporary shareholder meeting [30][31] - The company must provide adequate notice for shareholder meetings, including details on the agenda and voting procedures [62][64] Board of Directors and Management - The board of directors is responsible for the overall governance of the company, including the appointment of senior management [19][22] - The company has established an audit committee to oversee financial practices and ensure compliance with regulations [19] Financial Accounting and Auditing - The company is required to maintain a financial accounting system and conduct regular audits to ensure transparency and accountability [4][19] - Profit distribution and financial responsibilities are clearly defined within the company's articles of association [4][19] Amendments to Articles of Association - The articles of association can be amended following the procedures outlined in the document, requiring approval from the shareholders [10][26]

Core Viewpoint - China Jinshi (01380.HK) has entered into a conditional subscription agreement with Liu Desheng to issue 11.236 million shares at a subscription price of HKD 0.178 per share, totaling HKD 2 million [1] Group 1 - The subscription shares represent approximately 3.03% of the existing issued shares as of the announcement date and approximately 2.94% of the enlarged issued shares post-completion [1] - The proceeds from the subscription are intended for general working capital, business development, and expansion, including funding for the acquisition of mining rights in Chile [1]

Core Viewpoint - China Jinshi (01380) announced a conditional subscription agreement with six subscribers to issue a total of 95.56 million subscription shares at a price of HKD 0.178 per share, raising approximately HKD 17 million [1] Group 1 - The total number of subscription shares represents approximately 25.8% of the existing issued shares as of the announcement date and about 20.5% of the enlarged issued shares post-completion, assuming no other changes in issued shares [1] - The estimated total proceeds from the subscription are approximately HKD 17 million, with a net amount of about HKD 16.7 million after deducting related expenses, equating to a net subscription price of approximately HKD 0.175 per share [1] - The proceeds from the subscription are intended for general working capital purposes and for the development and expansion of the group's business, including funding for the acquisition of mining rights in Chile [1]

Core Viewpoint - Northern Mining (00433) has completed the subscription agreement, fulfilling all conditions precedent, with the subscription completed on August 18, 2025 [1] Group 1: Subscription Details - The subscriber has acquired a total of 2.4905 billion shares at a subscription price of HKD 0.03 per share [1] - The net proceeds from the subscription, after deducting professional fees and other related expenses, amount to approximately HKD 74.7 million [1] Group 2: Use of Proceeds - The company plans to use the net proceeds to repay bank loans and other borrowings under its current liabilities, as well as for general working capital [1]